MAIA BIOTECHNOLOGY INC (MAIA) Stock Price & Overview
NYSEARCA:MAIA • US5526411021
Current stock price
The current stock price of MAIA is 1.53 USD. Today MAIA is down by -2.55%. In the past month the price decreased by -22.33%. In the past year, price decreased by -1.29%.
MAIA Key Statistics
- Market Cap
- 56.656M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.73
- Dividend Yield
- N/A
MAIA Stock Performance
MAIA Stock Chart
MAIA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MAIA. When comparing the yearly performance of all stocks, MAIA turns out to be only a medium performer in the overall market: it outperformed 60.17% of all stocks.
MAIA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MAIA. The financial health of MAIA is average, but there are quite some concerns on its profitability.
MAIA Earnings
MAIA Forecast & Estimates
7 analysts have analysed MAIA and the average price target is 10.48 USD. This implies a price increase of 584.67% is expected in the next year compared to the current price of 1.53.
MAIA Groups
Sector & Classification
MAIA Financial Highlights
Over the last trailing twelve months MAIA reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 46.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -146.41% | ||
| ROE | -417.16% | ||
| Debt/Equity | 0 |
MAIA Ownership
MAIA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.8 | 398.492B | ||
| AMGN | AMGEN INC | 16.04 | 198.265B | ||
| GILD | GILEAD SCIENCES INC | 16.4 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.21 | 121.459B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 78.932B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.01 | 42.071B | ||
| INSM | INSMED INC | N/A | 30.073B | ||
| BIIB | BIOGEN INC | 11.29 | 27.136B | ||
| NTRA | NATERA INC | N/A | 26.973B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.95 | 23.353B | ||
| MRNA | MODERNA INC | N/A | 21.086B | ||
| EXAS | EXACT SCIENCES CORP | 340.74 | 19.713B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.84B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MAIA
Company Profile
MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. The company is headquartered in Chicago, Illinois and currently employs 13 full-time employees. The company went IPO on 2022-07-28. The firm's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
Company Info
IPO: 2022-07-28
MAIA BIOTECHNOLOGY INC
444 West Lake Street, Suite 1700, Suite 1700
Chicago ILLINOIS US
Employees: 13
Phone: 13124168592
MAIA BIOTECHNOLOGY INC / MAIA FAQ
What does MAIA do?
MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. The company is headquartered in Chicago, Illinois and currently employs 13 full-time employees. The company went IPO on 2022-07-28. The firm's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
What is the current price of MAIA stock?
The current stock price of MAIA is 1.53 USD. The price decreased by -2.55% in the last trading session.
Does MAIA stock pay dividends?
MAIA does not pay a dividend.
What is the ChartMill technical and fundamental rating of MAIA stock?
MAIA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is MAIA BIOTECHNOLOGY INC (MAIA) stock traded?
MAIA stock is listed on the NYSE Arca exchange.
Would investing in MAIA BIOTECHNOLOGY INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MAIA.